Subscribe to Search results

In her written statement to the Infected Blood Inquiry, Dr Diana Walford elaborated on the translation of a German note regarding a "publication" showing that American Kryobulin had a higher hepatitis risk.

Published on:

It was stated regarding a Hepatitis Survey that all the cases of clinical hepatitis and almost all asymptomatic hepatitis were confined to patients restricted to commercial concentrates. No significant differences between Hemofil and Kryobulin.

Published on:

Dr Saad Al-Ismail told the Inquiry that "maybe in retrospect it was probably a misplaced trust in the medicine licensing agency in the UK, in that we never used a product which is not licensed. We never used a product which has not proved to be efficacious."

Published on:

Speywood had a product licence to distribute Cutter's Koate, and by February 1980, Speywood later relabelled the Koate product and sold it as Humanate

Published on:

Speywood were informed that they could no longer sell relabelled Koate under the brand Humante as the CSM were unable to ensure the safety of the product.

Published on:

The last batch of Koate imported by Speywood was released by DHSS in February 1980.

Published on:

Dr Arthur Codd stated that it was known that viruses were transmitted in this way: "we knew there was always a risk there might be other things lurking there" adding that it had always been his advice to create a "pedigree herd" of volunteer donors in order to minimise the risk of infection. A decision was made to import commercial concentrates stating that "We could not have met demand at that time but we could have continued with the older products until Britain became self-sufficient."

Published on:

Professor Zuckerman told Michael Gillard that he had visited Immuno in Vienna, and thought it was a poor facility, which lacked medical back-up and had "dubious sources of plasma".

Published on:

The New England Journal of Medicine carried an article suggesting the recorded cases of the principal symptoms included in the syndrome might only represent the tip of the iceberg in terms of the prevalence of conditions associated with AIDS.

Published on:

It was reported to the World Congress of Blood Transfusion (Budapest) that is was suspected in the US that an infective agent in blood concentrates resulted in people with haemophilia dying of AIDS.

Published on:

Alpha confirmed that until further notice it would 'not be using the cryoprecipitated material from plasma from hepatitis B surface antibody donors in the manufacture of Antihemophilic Factor (Human).'

Published on:

Alpha confirmed that it had "voluntarily suspended until further notice the use of cryoprecipitated material from hepatitis B surface antibody donors in the manufacture of Antihemophilic Factor (Human)."

Published on:

Dr Denis Donohue of the FDA asked pharmaceutical companies to stop using blood collected from donors likely to have high levels of antibodies to Hepatitis.

Published on:

The Morbidity and Mortality Weekly report by the Centers for Disease Control reported 593 cases of AIDS, 243 of whom had died. It was reported that the CDC had been notified of 684 individuals who had been diagnosed with Kaposi's sarcoma and/or serious opportunistic infections resulting from an acquired immune deficiency and that at least 260 (41%) had died.

Published on:

By November 1982 the MMWR had reported 788 AIDS cases.

Published on:

It was reported that a baby in San Francisco had developed symptoms of AIDS after receiving transfusions. One of those transfusions had been given by a donor who was subsequently diagnosed with AIDS.

Published on:

Dr Craske set out various theories as to the aetiology of AIDS, including "possibly the transfusion of commercial blood concentrates". He noted that there was a considerable delay between occurrence of initial symptoms and diagnosis, and that mortality was high.

Published on:

Dr Craske submitted his report on AIDS to the UK Haemophilia Centre Directors' Hepatitis Working Party

Published on:

Drs Craske, Rizza and Bloom sent a circular letter to the Director of the Oxford Haemophilia Centre providing papers to enable a system for the reporting of possible AIDS cases to be set up "as quickly as possible."

Published on:

Dr Charles Rizza wrote in a study report that "By the end of 1982 it was clear that [recipients of blood products were] at risk of developing AIDS."

Published on: